Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $74.6652W HIGH $96.29
Volume
927.43 K
Value Traded
408.92 M
Short % Float
1.68%
Days to Cover
2.5
+2.72%Week
+3.18%1 Month
+7.89%3 Month
+7.34%6 Month
-7.89%5 Year
+6,649.91%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
51.76 B
EPS (TTM)
1.74
P/E Ratio
51.39
Ent. Value
48.03 B
Total Shares
575.63 M
Float Shares
569.39 M
Insiders
1.22%
Institutions
93.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EW Catalyst Timeline
Dated clinical, regulatory and corporate events for Edwards Lifesciences Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Edwards Lifesciences Corporation
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How EW actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Edwards Lifesciences Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every EW program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lippis Daniel J.Officer (CVP, TAVR) | Option | 619 40,652.91 held | $72.68 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EW
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.4 % (-30 %) | 75.53 M | 834.90 K | -32.16% ( -395.70 K) |
EW Institutional Ownership Trends
EW Short Interest
Shares sold short, counted twice a month.
1.68%
Short % of Float
of tradable shares sold short
9.5M
Shares Sold Short
+5.0% vs prior count
2.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EW ranks across every disease it competes in
Competitive Position is a premium feature
See how EW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEW News
EWFDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
Edwards Lifesciences received FDA approval for its PASCAL Precision system, designed for tricuspid valve repair. This system aims to enhance the quality of life for patients suffering from symptomatic severe tricuspid regurgitation who are at intermediate or higher surgical risk. The approval marks a significant advancement in treatment options for these patients.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on November 4, 2026
Edwards Lifesciences will announce its Q3 2026 operating results on November 4, 2026. The announcement will be followed by a conference call at 5:00 p.m. ET to discuss the results. Investors can participate by dialing the provided numbers or accessing the call via the company's website.
Read more →EWEdwards Lifesciences to Host Investor Event in Conjunction With TCT
Edwards Lifesciences has announced an investor event coinciding with the TCT annual scientific symposium in San Diego. Scheduled for November 2, the event will feature a live Q&A session with physicians and the company's management team. A live webcast will also be available for broader access to the discussions.
Read more →EWEdwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve tailored for pediatric patients with congenital heart disease. This innovative valve addresses the ongoing need for pulmonary valve replacement in children, marking a significant advancement in pediatric cardiac care.
Read more →EWEdwards Lifesciences Comments on TAVR National Coverage Decision
Edwards Lifesciences has expressed satisfaction with the recent national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) issued by CMS. The company views this policy update as a crucial advancement in enhancing patient access to TAVR procedures. Additionally, it emphasizes the importance of a collaborative approach through a multidisciplinary Heart Team in managing aortic stenosis.
Read more →EWEdwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
Edwards Lifesciences Corporation will present at the Deutsche Bank Healthcare Summit on September 16, 2026. CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. A live webcast of the presentation will be available on their investor relations website.
Read more →EWEdwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences reported a strong financial performance for Q2 2026, with sales rising 13.6% to $1.74 billion. TAVR sales also showed significant growth, increasing by 11.3%. The company's adjusted EPS was reported at $0.78, reflecting robust earnings. Recent clinical data further supports their leading position in the market.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on July 23, 2026
Edwards Lifesciences plans to announce its operating results for Q2 2026 on July 23. The company will host a conference call at 5:00 p.m. ET to discuss these results. Participants can join the call via phone or access it through the company's Investor Relations website.
Read more →EWEdwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
The article discusses Edwards Lifesciences' contributions to structural heart leadership, highlighted by their expanding body of scientific evidence presented at the New York Valves event. However, specific details about the evidence or findings are not provided in the text.
Read more →EWEdwards Lifesciences Announces Appointment of CFO
Edwards Lifesciences has announced the appointment of a new Chief Financial Officer. The announcement is part of the company's ongoing efforts to strengthen its leadership team. Further details regarding the new CFO's background and experience were not provided in the article.
Read more →EWTen-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
Edwards Lifesciences has released ten-year pivotal data showcasing the long-term durability of its Resilia Tissue. This data is expected to influence future clinical applications and enhance the understanding of the product's performance over an extended period. The findings could play a significant role in the company's ongoing research and development efforts.
Read more →EWEdwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
Edwards Lifesciences announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 12, 2026. CEO Bernard Zovighian will engage in a fireside chat at 3:40 p.m. PT, with a live webcast available for investors. The event underscores the company's commitment to patient-focused innovations.
Read more →EWEdwards Lifesciences Reports First Quarter Results
Edwards Lifesciences reported a strong financial performance for Q1 2026, with sales increasing by 16.7% to $1.65 billion. The company raised its full-year guidance for sales growth and adjusted EPS, reflecting robust demand for its TAVR and TMTT products. Despite some challenges, including a significant impairment loss, the overall outlook remains positive as the company focuses on innovative therapies.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on April 23, 2026
Edwards Lifesciences has announced an upcoming earnings conference call scheduled for April 23, 2026. The event aims to provide insights into the company's financial performance and future outlook. Further details regarding the agenda and participation will likely be shared closer to the date.
Read more →EWTwo Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
Edwards Lifesciences has released two-year data on its EVOQUE System, highlighting significant and sustained benefits for patients. The findings suggest that the system continues to provide positive outcomes over an extended period. This data reinforces the effectiveness of the EVOQUE System in clinical settings.
Read more →EWEDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
Edwards Lifesciences reported strong financial results for Q4 and the full year of 2025, with sales increasing 13.3% to $1.57 billion. The company has bolstered its outlook for 2026, projecting sales growth of 8-10% and adjusted EPS between $2.90 and $3.05. Notable performance was seen in TAVR and TMTT segments, highlighting a commitment to innovation in heart therapies. Edwards aims to leverage its extensive research and prior trial successes to support continued growth in upcoming years.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on February 10, 2026
Edwards Lifesciences plans to announce its operating results for Q4 2025 on February 10, 2026. The announcement will be followed by a conference call at 5:00 p.m. ET to discuss the results. Participants can join the call via specified phone numbers or through the company's Investor Relations website.
Read more →EWEdwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference
Edwards Lifesciences Corporation will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CFO Scott Ullem is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible later.
Read more →EWFDA Approves Edwards Lifesciences’ SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, marking it as the first transseptal transcatheter therapy for mitral regurgitation. This system is designed for patients who are not candidates for surgery or other treatments. The approval is supported by successful trial data demonstrating significant improvements in patient outcomes.
Read more →EWEdwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
Edwards Lifesciences reaffirmed its strategy for sustainable growth at its annual investor conference, highlighting its commitment to innovative therapies for structural heart diseases. The company aims to address unmet needs in aortic stenosis, mitral regurgitation, and other conditions. CEO Bernard Zovighian emphasized the importance of delivering differentiated innovations to improve patient care and outcomes. Edwards is focused on expanding its portfolio and enhancing patient access to its therapies.
Read more →About Edwards Lifesciences Corporation
HeadquartersONE EDWARDS WAY, IRVINE, CA, 92614
BIOPHARMAWATCH ELITE PLUS
Trade the next EW catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime